Pfizer Inc.

Pfizer Inc. is an American multinational pharmaceutical and biotechnology company that discovers, develops, manufactures, and commercializes a broad portfolio of prescription medicines and vaccines, generating $62.6 billion in revenue in fiscal 2025. It is one of the largest research-based biopharmaceutical companies in the world, with a commercial presence in more than 125 countries, approximately 75,000 employees, and a 176-year history that runs from a fine-chemicals shop in Brooklyn to the co-development of the first authorized mRNA vaccine.

This is a story about a company navigating one of the most consequential transitions in its modern history. The wind-down of the COVID-era revenue surge has left Pfizer with a balance sheet scarred by a $67 billion debt load, a stock trading near eight-year lows, and a market that appears to be pricing the post-pandemic portfolio at roughly liquidation value after accounting for the debt. The core business, however, is not broken: non-COVID revenue grew 7% operationally in the first quarter of 2026, the oncology franchise is gaining commercial momentum, and the recent Vyndamax patent settlement transformed the company's cash-flow profile through the early 2030s. The file turns on a single question: whether the $43 billion Seagen acquisition and a pipeline rich in late-stage oncology and obesity assets can produce enough value to offset roughly $14–15 billion in upcoming loss-of-exclusivity headwinds before the company's financial flexibility is exhausted.

The answer is not obvious, and that is what makes Pfizer interesting at $26 a share. The dividend yield exceeds 6.5%, the pipeline has more late-stage shots on goal than the current valuation credits, and the Vyndamax settlement removed the most acute near-term cliff. But the margin for error is narrow: leverage at 2.8x, a payout ratio that will test free cash flow through the LOE trough, and a portfolio whose core franchises face well-understood competitive and regulatory pressures. The next twelve to eighteen months — a period dense with Phase III oncology readouts, the obesity program's advancement, and the generic exposure timeline for Eliquis — will determine which side of the transition this company lands on.